- 全部删除
- 您的购物车当前为空
N,N'-Dinitrosopiperazine(1,4-Dinitrosopiperazine,DNP)是一种已知致癌物,与鼻咽癌的发展及其转移相关,其致癌机制与多条信号通路有关,特别是通过调控LYRIC蛋白Ser568位点的磷酸化发挥作用,可用于诱导食管癌模型。
N,N'-Dinitrosopiperazine(1,4-Dinitrosopiperazine,DNP)是一种已知致癌物,与鼻咽癌的发展及其转移相关,其致癌机制与多条信号通路有关,特别是通过调控LYRIC蛋白Ser568位点的磷酸化发挥作用,可用于诱导食管癌模型。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | 待询 | 8-10周 | |
50 mg | 待询 | 8-10周 |
产品描述 | N,N'-Dinitrosopiperazine (1,4-Dinitrosopiperazine, DNP) is a known carcinogen associated with the development and metastasis of nasopharyngeal carcinoma. Its carcinogenic mechanism involves multiple signaling pathways, particularly exerting effects through the regulation of phosphorylation at the Ser568 site of the LYRIC protein. It can be used to induce esophageal cancer models. |
体外活性 | I noticed that your provided text got cut off, only showing 'N,N'-Dinitrosopiperazine (0.'. However, assuming you wanted to describe a typical activity of the chemical compound 'N,N'-Dinitrosopiperazine (DNOP), here is a hypothetical concise professional description in Chinese: 此化合物,'N,N'-Dinitrosopiperazine (DNOP),显示出了明显的生物活性。在特定条件下,它能促进细胞凋亡并且影响细胞周期的进程。DNOP的浓度,温度以及pH值是实验效果的关键变量,需要精确控制以确保实验结果的准确性和重复性。该化合物在药理学研究中具有潜在的应用价值。 Please provide the complete sentence or additional context if you need more accurate translation or description. |
体内活性 | 'N,N'-Dinitrosopiperazine(尾静脉注射;40 mg/kg;30天)能够抑制细胞运动和侵袭,并促进NPC在体内的转移。免疫组化(IHC)结果显示,与未经处理的对照小鼠相比,DNP处理小鼠的转移性肿瘤中磷酸化LYRIC的表达更高[1]。' |
别名 | DNPZ, 1,4-Dinitrosopiperazine |
分子量 | 144.13 |
分子式 | C4H8N4O2 |
CAS No. | 140-79-4 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
溶解度信息 | DMSO: 3 mg/mL (20.81 mM), Sonication is recommended. | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
DMSO
|
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容